Free Trial
→ $0. Later: $29.97. (From Profits Run) (Ad)tc pixel
NASDAQ:EMBC

Embecta Q4 2026 Earnings Date & Estimates

Embecta logo
$6.22 -0.21 (-3.19%)
As of 11:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Embecta is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q4 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Embecta in Q4 2026

Embecta is expected to post earnings of $0.31 per share on revenue of $267.37 million. In the same quarter a year earlier Embecta reported $0.50 per share on revenue of $263.30 million. Embecta last reported on August 7, 2026, posting $0.56 per share and beating the $0.2658 consensus estimate. Embecta has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.31
Expected Revenue
$267.37 million
Prior-Year EPS
$0.50
Prior-Year Revenue
$263.30 million
Expected EPS Growth
-38.0%
Expected Revenue Growth
+1.5%

Recent Track Record

Last Reported
Q3 2026
Last Quarter EPS
$0.56 (Beat by +$0.2942)
Last Quarter Revenue
$271.70 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q4 2026 Call

Embecta Q4 2026 Earnings FAQ

Embecta (NASDAQ:EMBC) is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Embecta's Q4 2026 earnings conference call is scheduled for Tuesday, November 24, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Embecta to post earnings of $0.31 per share for Q4 2026.

The consensus revenue estimate for Embecta is $267.37 million for Q4 2026.

Embecta Earnings Headlines

Why Embecta Bears Were Right Before A 54% Drop
November 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-embecta-bears-were-54-042700288.html
Embecta (EMBC)
September 30, 2026  |  es.investing.comhttps://es.investing.com/equities/embecta
Trump compared today's market to 1929
President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they did. Before a single vote was counted, the IMF flagged markets as increasingly exposed to a sharp correction, Ray Dalio called conditions a classic bubble, and Peter Schiff said a downturn could hit regardless of the outcome.tc pixel
November 13 at 1:00 AM  |  USA Capital Gold (Ad)
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366757/0/en/embecta-corp-nasdaq-embc-shareholder-investigation-alert-bernstein-liebhard-investigates-potential-breaches-of-fiduciary-duty.html
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355208/0/en/embecta-corp-nasdaq-embc-shareholder-investigation-alert-bernstein-liebhard-investigates-potential-breaches-of-fiduciary-duty.html
embecta to Participate in Investor Events
August 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353720/0/en/embecta-to-participate-in-investor-events.html
See More Embecta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Embecta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Embecta and other key companies, straight to your email.

About Embecta

Embecta (NASDAQ:EMBC) is a medical device company focused on products for people who use insulin to manage diabetes. Its portfolio includes pen needles, insulin syringes and safety injection devices, serving both individuals and healthcare professionals.

The company was formed in 2022 when Becton, Dickinson and Company (BD) separated its diabetes care business into an independent company. Embecta continues to build on that business’s history of developing injection devices for diabetes care.

Embecta serves customers in markets around the world. Its products are designed to support insulin delivery and help meet the needs of people with diabetes across a range of care settings.

View Embecta Profile
Earnings Tools